Fig. 2

Harmol reduced HSV-1 F and HSV-1/153 replication in vitro. A Vero cells were pretreated with ACV (1 µM) or harmol (0, 3.125, 6.25, 12.5, 25, 50 µM) for 2 h, subsequently, they were challenged by HSV-1 F (MOI = 0.5) for 24 h. The HSV-gD-1 (green) expression was identified by in-cell western assay, which was further normalized by DRAQ5 (red). B The expression of gD-1 mRNA was detected by qPCR analysis. C Anti-HSV-1 effect (%) was counted by in-cell western assay. D, E HSV-1-infected Vero cells were treated with different concentrations of harmol or ACV. The supernatant was collected at 48 h and the viral titers were measured by TCID₅₀ assay. ACV treatment at 1 µM was used as a positive control. All experiments were duplicated three times, and corresponding results were shown. F, G Vero cells were pretreated with various concentrations of harmol (0, 3.125, 6.25, 12.5, 25, 50 µM) for 2 h, and then they were infected with HSV-1/153 (MOI = 0.5) for 48 h. gD-1 protein expression (green) and DRAQ5 (red) were determined by In-cell Western assay. H Anti-HSV-1 effect (%) was shown. I The supernatant was collected at 48 h and the viral titers were measured by a TCID₅₀ assay. All trials were duplicated three times, and corresponding results were shown. Data expressed as Mean ± SD (ns: non-significant, ^** P < 0.01, ^*** P < 0.001)